BAMF Health dosed the first patient enrolled in a Phase 1 prostate cancer therapy clinical trial sponsored by ARTBIO, Inc. (“ARTBIO”). Patients will receive AB001, a promising new alpha radioligand therapy (ART) in development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). ARTBIO is a clinical-stage radiopharmaceutical company developing a new class of ARTs to treat a range of cancers.
BAMF Health Medical Director and principal investigator for the trial, Dr. Brandon Mancini, said, “AB001 PSMA-targeted radioligand therapy has the potential to reshape the treatment landscape for advanced prostate cancer and bring a new option to patients with metastatic castration-resistant prostate cancer who urgently need additional pathways forward.”
In a prior Phase 0 theranostic clinical study, AB001, which is labeled with an alpha emitter Lead-212 (Pb212), identified potential advantages compared with other radioligand therapies. Alpha particles have a high linear energy transfer, which causes double-stranded DNA breaks in tumor cells. Additionally, the short half-life, high stability in carrier molecules, and ability to work in conjunction with imaging such as SPECT/CT make ARTs more desirable than beta-emitter therapies.
“On behalf of ARTBIO, I want to express my sincere gratitude to the BAMF team who have been amazing partners to us,” said Dr. Margaret Yu, Chief Medical Officer of ARTBIO. “The first patient dosing with AB001 marks a long-awaited milestone and reflects years of dedication and passion by our world-class team.”
As the first site to launch this trial and the first site to dose a patient, BAMF’s clinical trials team has been instrumental in assisting ARTBIO with trial setup, processes, and logistics.Our team’s expertise in launching and executing complex trials ensures promising treatment options are available to patients as soon as possible.
“The strong collaboration and partnership between our teams resulted in a fast and efficient startup process,” said BAMF Health Supervisor of Research Nuclear Medicine Tina Brennan. “The ARTBIO team was incredibly engaged, and we look forward to seeing the impact AB001 could have on patients with mCRPC.”
For more information about the trial and inclusion criteria, visit: https://www.bamfhealth.com/clinical-trials/#a-9901.
About ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company redefining cancer care by creating a new class of alpha radioligand therapies (ARTs). The unique ARTBIO approach selects the optimal alpha-precursor isotope (Pb212) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety. The company’s AlphaDirect™ technology, a first-of-its-kind 212Pb isolation method, enables a distributed manufacturing approach for the reliable production and delivery of ARTs. ARTBIO is advancing multiple pipeline programs with lead program AB001 in metastatic castration resistant prostate cancer currently in first in human trials. ARTBIO is shaped by a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy conducted at the University of Oslo and Norway’s Radium Hospital. For more information, visit www.artbio.com, and follow us on LinkedIn.
